Synbio International Inc. (OTC: SYIN) has named Desiree Cain, CPA, MBA as Chief Financial Officer and board member, effective immediately. Ms. Cain brings more than 25 years of experience in corporate finance, accounting, and strategic growth management.
In her new role, Ms. Cain will manage all financial operations, accounting, regulatory reporting, and compliance with SEC and OTC Markets standards. She will also establish governance and risk management systems aligned with public company best practices.
“Her deep financial expertise and proven strength in investor relations will enhance our corporate governance, sharpen our capital-raising strategies, and bring valuable strategic insight as we enter our next phase of growth,” said CEO Claudio Solitario.
Synbio International focuses on AI-driven medical diagnostics pursued through strategic partnerships and research collaborations aimed at improving healthcare quality and empowering providers.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.